NDAINTRAVENOUSINJECTABLEPriority Review
Approved
Dec 1977
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
THALLOUS CHLORIDE TL 201 (thallous chloride tl-201) by Lantheus Medical Imaging is 201 with no carrier added accumulates in viable myocardium in a manner analogous to that of potassium. First approved in 1977.
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Thallous Chloride Tl-201 is a radiopharmaceutical diagnostic agent approved in 1977 for myocardial perfusion imaging. It accumulates in viable myocardium analogous to potassium and is used to detect areas of myocardial infarction and transient ischemia during exercise stress testing. The agent visualizes perfusion defects as 'cold' or nonlabeled regions, helping clinicians identify coronary artery stenosis and ischemic territories.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100); team focus likely shifting to lifecycle extension or transition management.
Mechanism of Action
201 with no carrier added accumulates in viable myocardium in a manner analogous to that of potassium. Experiments in healthy subjects using labeled microspheres have shown that the myocardial distribution of thallous chloride Tl 201 correlates with regional perfusion. In clinical studies, Thallous…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect the mature, declining commercial phase of this legacy radiopharmaceutical. Career opportunities on this product are limited and primarily focused on sustaining existing business rather than growth or innovation.
Product Manager
Worked on THALLOUS CHLORIDE TL 201 at Lantheus Medical Imaging? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.